27 Aug 2020 Governance

Leukaemia UK appoints new CEO

The trustees of Leukaemia UK are delighted to announce that they have appointed Fiona Hazell as CEO of Leukaemia UK. Fiona brings a strong track record in not-for-profit leadership, helping lead two mergers to create the UK’s largest breast cancer charity, as well as critical policy and campaigning successes, in her role as Director of Communications, Engagement & Influencing at Breast Cancer Now since 2014.

Chris Corbin OBE, Chairman of Leukaemia UK Trustees and a Director of Corbin & King, said:

“We are thrilled to welcome Fiona as our new CEO. Fiona brings a wealth of experience in the cancer charity sector and has outstanding leadership qualities. We are confident Fiona will lead Leukaemia UK to make an even more significant impact to those affected by leukaemia and other blood cancers. With blood cancer being the 5th most common type of cancer in the UK, it is essential that we continue to deliver on our objective to fund more vital research and care, especially during these unprecedented times. We look forward to having Fiona at the helm of Leukaemia UK to help deliver this mission.”

Fiona Hazell said:

“I’m hugely excited to be joining the Leukaemia UK team as CEO to drive progress for all those affected by leukaemia and other blood cancers – the UK’s third biggest cancer killer. Now more than ever, blood cancer patients and their families across the UK, need new hope for the future and greater support day-to-day and I look forward to collaborating with our incredible supporters and the wider blood cancer community to meet that challenge.”

Fiona begins on 9th September 2020.

Please do not hesitate to contact us on contribute@leukaemiauk.org.uk if you have any questions or queries.

Find out more about our ground-breaking research and care projects.

September is Blood Cancer Awareness Month, find out ways you can get involved.

Related posts

1 in 4 leukaemia patients in England experiences an avoidable delay in diagnosis

18 September 2025

1 in 4 leukaemia patients in England experiences an avoidable delay in diagnosis

A first of its kind study, commissioned by Leukaemia UK, has revealed that a quarter (26%) of leukaemia patients in England experience avoidable delays in their diagnosis, resulting in a…

A new clinical trial announced

21 May 2020

A new clinical trial announced

A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.

Less than 1% of Brits can identify all the most common symptoms of one of the deadliest types of cancer

4 September 2023

Less than 1% of Brits can identify all the most common symptoms of one of the deadliest types of cancer

New research launched today by Leukaemia Care and Leukaemia UK reveals that less than 1% (0.4%) of UK adults can accurately identify the four most common symptoms of leukaemia –…

Lymphoma: Understanding relapse and treatment resistance

11 January 2019

Lymphoma: Understanding relapse and treatment resistance

Dr Dinis Calado, The Francis Crick Institute and Project Grant Holder